Karen Springfield
Nurse Practitioner · Pueblo, CONPI 1760766430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$710
- AstraZeneca$470
- Pfizer$417
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$366
- Johnson & Johnson$163
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,797100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,026 |
| Novo Nordisk | 55 | $710 |
| AstraZeneca | 29 | $470 |
| Pfizer | 32 | $417 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $366 |
| Johnson & Johnson | 11 | $163 |
| Amgen | 10 | $148 |
| Lilly USA, LLC | 9 | $142 |
| Novartis | 6 | $137 |
| Astellas Pharma US Inc | 7 | $127 |
| GSK | 6 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Sunovion Pharmaceuticals Inc. | 5 | $74 |
| Sumitomo Pharma America, Inc. | 4 | $71 |
| Idorsia Pharmaceuticals US Inc | 4 | $69 |
| Exact Sciences | 4 | $62 |
| Eisai Inc. | 4 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Boehringer Ingelheim | 4 | $55 |
| Bayer | 3 | $48 |
| Organon | 3 | $48 |
| Paratek Pharmaceuticals, Inc. | 3 | $47 |
| Seqirus USA Inc | 3 | $39 |
| Merck | 2 | $31 |
| Vertex | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Clarus Therapeutics Inc. | 3 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Viiv Healthcare Company | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$4,797 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $79,237 |
| TrulicityDulaglutide | 45 | $77,106 |
| EliquisApixaban | 27 | $36,696 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $21,993 |
| JanuviaSitagliptin Phosphate | 13 | $21,961 |
| MounjaroTirzepatide | 13 | $19,917 |
| GemtesaVibegron | 14 | $14,639 |
| XareltoRivaroxaban | 12 | $13,477 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $9,346 |
| Enoxaparin Sodium | 13 | $5,437 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,614 |
| Rosuvastatin Calcium | 290 | $3,161 |
| Levothyroxine Sodium | 260 | $2,804 |
| Omeprazole | 173 | $2,513 |
| Lidocaine | 12 | $2,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $142 | $97,02358 claims |
| Novo NordiskOzempic | $710 | $79,23770 claims |
| PfizerEliquis | $417 | $36,69627 claims |
| GSKTrelegy Ellipta | $103 | $21,99318 claims |
| MerckJanuvia | $31 | $21,96113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $71 | $14,63914 claims |
| Johnson & JohnsonXarelto | $163 | $13,47712 claims |
| AstraZenecaSymbicort | $470 | $9,34628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Pueblo
- Kara HartPueblo$142K
- Linda JacksonPueblo$5K
- Deborah HinnenColorado Springs$388K
- Christina HansonLone Tree$381K
- Amy SidorskiAurora$97K
- Lori WenzGrand Junction$54K
- Lisa KeithColorado Springs$52K
- Victoria SegroEnglewood$29K
- Christina ProulxDenver$28K
- Jose Diaz LeoDenver$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.